Amgen’s Stealth Enbrel Patent May Block Biosimilars; Scenario May Apply To Other Biologics
Amgen’s patent may keep Enbrel biosimilars off the market until at least 2028. Other biosimilar sponsors could face similar submarine patents that derail their commercialization plans.
You may also be interested in...
Court rejects Sandoz's arguments that patents covering Enbrel's active ingredient and method of manufacture are invalid; decision comes three years after FDA approved Sandoz's biosimilar.
For second time Sandoz faces claims it is trying to reap benefits of biosimilars law without meeting its obligations.
Etanercept biosimilar could face more complications on both patent and review front than Zarxio experienced.